$1.59
1.24%
Nasdaq, Mon, Nov 25 2024
ISIN
US0088751062
Symbol
AIKI
Sector
Industry

AIkido Pharma Inc Stock price

$1.59
-0.19 10.67% 1M
-0.59 27.06% 6M
-1.00 38.61% YTD
-0.59 27.06% 1Y
-11.28 87.64% 3Y
-16.82 91.36% 5Y
-1,600.10 99.90% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.02 1.24%
ISIN
US0088751062
Symbol
AIKI
Sector
Industry

Key metrics

Market capitalization $9.98m
Enterprise Value $5.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.47
P/S ratio (TTM) P/S ratio 0.79
P/B ratio (TTM) P/B ratio 0.26
Revenue growth (TTM) Revenue growth 1,117.50%
Revenue (TTM) Revenue $12.59m
EBIT (operating result TTM) EBIT $-14.58m
Free Cash Flow (TTM) Free Cash Flow $-16.65m
Cash position $7.17m
EPS (TTM) EPS $-3.75
Short interest 1.39%
Show more

Is AIkido Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

AIkido Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast AIkido Pharma Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast AIkido Pharma Inc:

Buy
100%

Financial data from AIkido Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
13 13
1,122% 1,122%
100%
- Direct Costs 0.48 0.48
45% 45%
4%
12 12
1,076% 1,076%
96%
- Selling and Administrative Expenses 26 26
33% 33%
208%
- Research and Development Expense - -
-
-
-14 -14
26% 26%
-112%
- Depreciation and Amortization 0.48 0.48
-
4%
EBIT (Operating Income) EBIT -15 -15
24% 24%
-116%
Net Profit -23 -23
2% 2%
-180%

In millions USD.

Don't miss a Thing! We will send you all news about AIkido Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Spherix Incorporated, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. The company's platform consists of patented technology from leading universities and researchers and in the process of developing an innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer. Spherix Incorporated was founded in 1967 and is based in New York, New York.

Head office United States
CEO Anthony Hayes
Employees 28
Founded 1967
Website www.dominariholdings.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today